2018 American Transplant Congress
The Infusion with a Difference: Patient Experiences with Belatacept
Yale University, New Haven, CT.
Introduction: The results of the BENEFIT trial led to the FDA approval of the novel anti-rejection agent belatacept (bela) in 2011. In addition to its…2018 American Transplant Congress
Efficacy of Current Educational Interventions in Improving Living Donor Kidney Transplantation Rates
McGill Unversity Health Center, Montreal, Canada.
IntroductionLack of knowledge and discomfort approaching a donor are two of the most common recognized, recipient-level barriers to living donor kidney transplantation (LDKT). To address…
American Transplant Congress abstracts